[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Browse LTA

Summary
SymbolLTA
Namelymphotoxin alpha
Aliases TNFSF1; LT; TNF superfamily member 1; TNFB; lymphotoxin alpha (TNF superfamily, member 1); LT-alpha; TNF sup ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted. Membrane. Note=The homotrimer is secreted. The heterotrimer is membrane-associated.
Domain PF00229 TNF(Tumour Necrosis Factor) family
Function

Cytokine that in its homotrimeric form binds to TNFRSF1A/TNFR1, TNFRSF1B/TNFBR and TNFRSF14/HVEM. In its heterotrimeric form with LTB binds to TNFRSF3/LTBR. Lymphotoxin is produced by lymphocytes and cytotoxic for a wide range of tumor cells in vitro and in vivo.

> Gene Ontology
 
Biological Process GO:0001666 response to hypoxia
GO:0001819 positive regulation of cytokine production
GO:0002237 response to molecule of bacterial origin
GO:0002250 adaptive immune response
GO:0002437 inflammatory response to antigenic stimulus
GO:0002439 chronic inflammatory response to antigenic stimulus
GO:0002443 leukocyte mediated immunity
GO:0002449 lymphocyte mediated immunity
GO:0002455 humoral immune response mediated by circulating immunoglobulin
GO:0002460 adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002544 chronic inflammatory response
GO:0002676 regulation of chronic inflammatory response
GO:0002678 positive regulation of chronic inflammatory response
GO:0002697 regulation of immune effector process
GO:0002699 positive regulation of immune effector process
GO:0002703 regulation of leukocyte mediated immunity
GO:0002705 positive regulation of leukocyte mediated immunity
GO:0002706 regulation of lymphocyte mediated immunity
GO:0002708 positive regulation of lymphocyte mediated immunity
GO:0002712 regulation of B cell mediated immunity
GO:0002714 positive regulation of B cell mediated immunity
GO:0002819 regulation of adaptive immune response
GO:0002821 positive regulation of adaptive immune response
GO:0002822 regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002824 positive regulation of adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains
GO:0002861 regulation of inflammatory response to antigenic stimulus
GO:0002863 positive regulation of inflammatory response to antigenic stimulus
GO:0002874 regulation of chronic inflammatory response to antigenic stimulus
GO:0002876 positive regulation of chronic inflammatory response to antigenic stimulus
GO:0002889 regulation of immunoglobulin mediated immune response
GO:0002891 positive regulation of immunoglobulin mediated immune response
GO:0002920 regulation of humoral immune response
GO:0002922 positive regulation of humoral immune response
GO:0002923 regulation of humoral immune response mediated by circulating immunoglobulin
GO:0002925 positive regulation of humoral immune response mediated by circulating immunoglobulin
GO:0006959 humoral immune response
GO:0007584 response to nutrient
GO:0009991 response to extracellular stimulus
GO:0010720 positive regulation of cell development
GO:0014009 glial cell proliferation
GO:0014013 regulation of gliogenesis
GO:0014015 positive regulation of gliogenesis
GO:0016064 immunoglobulin mediated immune response
GO:0019724 B cell mediated immunity
GO:0031349 positive regulation of defense response
GO:0031667 response to nutrient levels
GO:0032103 positive regulation of response to external stimulus
GO:0032496 response to lipopolysaccharide
GO:0032609 interferon-gamma production
GO:0032649 regulation of interferon-gamma production
GO:0032729 positive regulation of interferon-gamma production
GO:0033209 tumor necrosis factor-mediated signaling pathway
GO:0034612 response to tumor necrosis factor
GO:0036293 response to decreased oxygen levels
GO:0042063 gliogenesis
GO:0042493 response to drug
GO:0042742 defense response to bacterium
GO:0043900 regulation of multi-organism process
GO:0043901 negative regulation of multi-organism process
GO:0043903 regulation of symbiosis, encompassing mutualism through parasitism
GO:0044110 growth involved in symbiotic interaction
GO:0044116 growth of symbiont involved in interaction with host
GO:0044117 growth of symbiont in host
GO:0044126 regulation of growth of symbiont in host
GO:0044130 negative regulation of growth of symbiont in host
GO:0044144 modulation of growth of symbiont involved in interaction with host
GO:0044146 negative regulation of growth of symbiont involved in interaction with host
GO:0045926 negative regulation of growth
GO:0048144 fibroblast proliferation
GO:0048145 regulation of fibroblast proliferation
GO:0048147 negative regulation of fibroblast proliferation
GO:0048535 lymph node development
GO:0050727 regulation of inflammatory response
GO:0050729 positive regulation of inflammatory response
GO:0050769 positive regulation of neurogenesis
GO:0050830 defense response to Gram-positive bacterium
GO:0051962 positive regulation of nervous system development
GO:0060251 regulation of glial cell proliferation
GO:0060252 positive regulation of glial cell proliferation
GO:0070482 response to oxygen levels
GO:0071356 cellular response to tumor necrosis factor
GO:0098542 defense response to other organism
Molecular Function GO:0005125 cytokine activity
GO:0005126 cytokine receptor binding
GO:0005164 tumor necrosis factor receptor binding
GO:0032813 tumor necrosis factor receptor superfamily binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG hsa04060 Cytokine-cytokine receptor interaction
hsa04064 NF-kappa B signaling pathway
hsa04668 TNF signaling pathway
Reactome R-HSA-1280215: Cytokine Signaling in Immune system
R-HSA-168256: Immune System
R-HSA-5676594: TNF receptor superfamily (TNFSF) members mediating non-canonical NF-kB pathway
R-HSA-5668541: TNFR2 non-canonical NF-kB pathway
R-HSA-5669034: TNFs bind their physiological receptors
Summary
SymbolLTA
Namelymphotoxin alpha
Aliases TNFSF1; LT; TNF superfamily member 1; TNFB; lymphotoxin alpha (TNF superfamily, member 1); LT-alpha; TNF sup ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LTA and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between LTA and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
16985173lymphomaInhibit immunityOur findings strongly suggest that secondary lymphoid organs contain MSCs able to give rise to adipocytes, chondrocytes, osteoblasts, as well as fully functional B-cell supportive FRCs. In vitro, bone marrow-derived MSCs acquire a complete FRC phenotype in response to a combination of tumor necrosis factor-alpha and lymphotoxin-alpha1beta2. Moreover, MSCs recruit primary FL cells that, in turn, trigger their differentiation into FRCs, making them able to support malignant B-cell survival.
11875499colon carcinomaPromote immunityCTL and NK cells promote tumor cell apoptosis with delivery of perforin and granzymes directly into cells or through the extrinsic pathway, inducing apoptotic death by triggering death receptors by the TNF family of molecules, including TRAIL, TNF- , Fas ligand (FasL), and lymphotoxin (LT), thereby inducing apoptosis in cells.
Summary
SymbolLTA
Namelymphotoxin alpha
Aliases TNFSF1; LT; TNF superfamily member 1; TNFB; lymphotoxin alpha (TNF superfamily, member 1); LT-alpha; TNF sup ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LTA in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLTA
Namelymphotoxin alpha
Aliases TNFSF1; LT; TNF superfamily member 1; TNFB; lymphotoxin alpha (TNF superfamily, member 1); LT-alpha; TNF sup ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LTA in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.3820.722
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.7220.625
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-0.0250.988
729033130MelanomaallAnti-PD-1 (nivolumab) 26231.1260.103
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15112.0130.0578
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1030.927
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 481.7940.0174
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 281.1680.266
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0080.971
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LTA in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLTA
Namelymphotoxin alpha
Aliases TNFSF1; LT; TNF superfamily member 1; TNFB; lymphotoxin alpha (TNF superfamily, member 1); LT-alpha; TNF sup ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LTA. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLTA
Namelymphotoxin alpha
Aliases TNFSF1; LT; TNF superfamily member 1; TNFB; lymphotoxin alpha (TNF superfamily, member 1); LT-alpha; TNF sup ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LTA. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LTA.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLTA
Namelymphotoxin alpha
Aliases TNFSF1; LT; TNF superfamily member 1; TNFB; lymphotoxin alpha (TNF superfamily, member 1); LT-alpha; TNF sup ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LTA. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLTA
Namelymphotoxin alpha
Aliases TNFSF1; LT; TNF superfamily member 1; TNFB; lymphotoxin alpha (TNF superfamily, member 1); LT-alpha; TNF sup ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LTA expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLTA
Namelymphotoxin alpha
Aliases TNFSF1; LT; TNF superfamily member 1; TNFB; lymphotoxin alpha (TNF superfamily, member 1); LT-alpha; TNF sup ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LTA and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLTA
Namelymphotoxin alpha
Aliases TNFSF1; LT; TNF superfamily member 1; TNFB; lymphotoxin alpha (TNF superfamily, member 1); LT-alpha; TNF sup ......
Chromosomal Location6p21.3
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LTA collected from DrugBank database.
> Drugs from DrugBank database
 

  Details on drugs targeting LTA.
ID Name Drug Type Targets #Targets
DB00005EtanerceptBiotechC1QA, C1QB, C1QC, C1R, C1S, FCGR1A, FCGR2A, FCGR2B, FCGR2C, FCGR3A ......14